The emerging roles and mechanism of N6-methyladenosine (m6A) modifications in urologic tumours progression

Zhu, Wenhao; Zhao, Renshan; Guan, Xiaofei; Xu, Wenrong

doi:10.3389/fphar.2023.1192495

Cited by 3 publications

(1 citation statement)

References 168 publications

(230 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCa photothermal immunotherapy is also a treatment direction for PCa. Meclofenamic acid, a highly selective FTO inhibitor, can be combined with a gold nanorod-based nanoplatform to promote photothermal immunotherapy for PCa ( 139 ). Curcumin can inhibit the expression of m 6 A-dependent TNF receptor-associated factor 4 induced by ALKBH5 and YTHDF1 ( 140 ).…”

Section: Pca and M 6 Amentioning

confidence: 99%

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Pan,

Tong,

Ren

et al. 2024

Oncol Rep

View full text Add to dashboard Cite

Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to the late detection of the disease. PCa affects middle-aged males between the ages of 45 and 60 years, and is the highest cause of cancer-associated mortality in Western countries. As the most abundant and common mRNA modification in higher eukaryotes, N 6 -methyladenosine (m 6 A) is widely distributed in mammalian cells and influences various aspects of mRNA metabolism. Recent studies have found that abnormal expression levels of various m 6 A regulators significantly affect the development and progression of various types of cancer, including PCa. The present review discusses the influence of m 6 A regulatory factors on the pathogenesis and progression of PCa through mRNA modification based on the current state of research on m 6 A methylation modification in PCa. It is considered that the treatment of PCa with micro-molecular drugs that target the epigenetics of the m 6 A regulator to correct abnormal m 6 A modifications is a direction for future research into current diagnostic and therapeutic approaches for PCa.

show abstract

Section: Pca and M 6 Amentioning

confidence: 99%

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Pan,

Tong,

Ren

et al. 2024

Oncol Rep

View full text Add to dashboard Cite

show abstract

m6A RNA Methylation and Implications for Hepatic Lipid Metabolism

Ming,

Chen,

et al. 2024

DNA and Cell Biology

View full text Add to dashboard Cite

The m6A regulators in prostate cancer: molecular basis and clinical perspective

Cao,

Jia,

Duan

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second leading cause of cancer-related death among men in western countries. Evidence has indicated the significant role of the androgen receptor (AR) as the main driving factor in controlling the development of PCa, making androgen receptor inhibition (ARI) therapy a pivotal management approach. In addition, AR independent signaling pathways also contribute to PCa progression. One such signaling pathway that has garnered our attention is N6-Methyladenosine (m6A) signaling, which refers to a chemical modification on RNA with crucial roles in RNA metabolism and disease progression, including PCa. It is important to comprehensively summarize the role of each individual m6A regulator in PCa development and understand its interaction with AR signaling. This review aims to provide a thorough summary of the involvement of m6A regulators in PCa development, shedding light on their upstream and downstream signaling pathways. This summary sets the stage for a comprehensive review that would benefit the scientific community and clinical practice by enhancing our understanding of the biology of m6A regulators in the context of PCa.

show abstract

The emerging roles and mechanism of N6-methyladenosine (m6A) modifications in urologic tumours progression

Cited by 3 publications

References 168 publications

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

m6A RNA Methylation and Implications for Hepatic Lipid Metabolism

The m6A regulators in prostate cancer: molecular basis and clinical perspective

Contact Info

Product

Resources

About

The emerging roles and mechanism of N6-methyladenosine (m6A) modifications in urologic tumours progression

Cited by 3 publications

References 168 publications

Role of N6‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Role of N6‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

m6A RNA Methylation and Implications for Hepatic Lipid Metabolism

The m6A regulators in prostate cancer: molecular basis and clinical perspective

Contact Info

Product

Resources

About

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)